Sunday, November 15, 2026

Peer-Reviewed Clinical Evidence Platform

The research that matters, without the jargon.

Peer-reviewed breakthroughs in plain English alongside verified outcomes, evidence grades, and clinical study details for everyone from everyday readers to medical students.

ClearMed Editorial Digest500 briefings across 12 specialties121 Phase III & clinical practice

Indexed from PubMed, NEJM, The Lancet, JAMA, Nature MedicineSaved Library

Health Hubs:

Stage: Evidence:

Showing 14 briefings matching “statin”

Reset all filters

Filtered Archive

Matching Peer-Reviewed Briefings

Peer-Reviewed Clinical Digests · Verified Scientific Media

NEUROLOGY · PHASE I/II

Broccoli Compound Offers Hope for Friedreich Ataxia by Boosting Frataxin and Protecting Nerves

A naturally occurring compound in broccoli shows preclinical promise in treating Friedreich ataxia by boosting frataxin and protecting nerve cells, offering hope for an affordable, disease-modifying therapy. Friedreich ataxia currently lacks truly curative or broadly effective disease-modifying therapies.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readScienceDailyNov 12, 2026

NEUROLOGY · PHASE III

Broccoli Compound Shows Promise Against Friedreich Ataxia by Boosting Frataxin and Neuroprotection

A natural compound from broccoli significantly boosts frataxin levels and activates neuroprotective pathways in preclinical models of Friedreich ataxia, offering a promising, affordable disease-modifying therapy. Currently, there are no approved disease-modifying therapies for Friedreich ataxia, and patient management is predominantly symptomatic and supportive, encompassing physical therapy, cardiac interventions, and diabetes management.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readScienceDailyNov 12, 2026

NEPHROLOGY · REAL-WORLD COHORT

Estimating GFR: what it is, what it is not, and why prediction cannot settle the question

Equations are population tools; at the bedside, non-glomerular filtration rate determinants of both creatinine and cystatin C can mislead. Schultheiss et al. show that replacing Chronic Kidney Disease Epidemiology Collaboration with European Kidney Function Consortium cystatin C-based equations reclassifies women, but not men, into milder chronic kidney disease stages, while outcome prediction is unchanged.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readKidney InternationalNov 15, 2026

CARDIOLOGY · CLINICAL PRACTICE

Senior Statins: Short-Term Safety, Long-Term Questions

While stopping statins after 70 might initially seem safe for those without prior heart events, the long-term risks suggest a careful discussion with your doctor is essential. For years, the medical community has debated the optimal duration of statin therapy, especially as patients enter advanced age.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readScienceDailyNov 13, 2026

ONCOLOGY · PRECLINICAL

Fructose Uncovered as a Driver of Ovarian Cancer Metastasis Post-Chemotherapy

Fructose metabolism, particularly post-chemotherapy, may represent a novel and actionable therapeutic target to impede ovarian cancer metastasis. Ovarian cancer often presents at an advanced stage, and despite initial responses to chemotherapy, recurrence and metastasis remain the primary causes of morbidity and risk of death.

2/5 Preclinical

Evidence Meter · 2/5

Animal & Preclinical Data

Demonstrated in living animal models before large-scale human safety and dosing trials begin.

1 min readScienceDailyNov 12, 2026

CARDIOLOGY · PHASE III

Coronary Artery Calcium Scoring Challenges Traditional Statin Prescription Guidelines

Coronary Artery Calcium (CAC) guided statin initiation resulted in similar major cardiovascular event rates with fewer prescriptions and significantly improved patient adherence compared to traditional risk assessments. Current standard of care for primary prevention statin initiation heavily relies on calculated risk scores (e.g., ASCVD risk in the US), which estimate the 10-year risk of atherosclerotic cardiovascular disease events based on factors like age, sex, race, cholesterol levels, blood pressure, and diabetes status.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readScienceDailyNov 12, 2026

CARDIOLOGY · PHASE III

Coronary Artery Calcium Scoring: A New Paradigm for Statin Allocation and Adherence?

Using coronary artery calcium (CAC) scoring to guide statin initiation reduces statin prescriptions without compromising major cardiovascular event prevention, while significantly improving medication adherence. Current guidelines from bodies like the ACC/AHA primarily utilize traditional risk assessment tools, such as the Pooled Cohort Equations, to identify individuals at intermediate to high risk for atherosclerotic cardiovascular disease (ASCVD) who would benefit from statin therapy.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readScienceDailyNov 12, 2026

CARDIOLOGY · RANDOMIZED CLINICAL TRIAL

Statin-Ezetimibe Combination Therapy versus Statin Monotherapy in Atherosclerotic Cardiovascular Disease: A Prespecified Secondary Analysis of the Randomized Ez-PAVE Trial

Within a target-directed LDL-C-lowering strategy, cardiovascular efficacy (real-world effectiveness in the trial) and safety did not differ significantly, whether initiated as statin-ezetimibe combination therapy or as statin monotherapy, but combination therapy facilitated achievement of a lower LDL-C target. In a target-directed low-density lipoprotein cholesterol (LDL-C)-lowering strategy, the impact of the initial treatment regimen has not been investigated in patients with atherosclerotic cardiovascular disease.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readCirculationNov 7, 2026

INFECTIOUS DISEASE · PHASE III

Imipenem-cilastatin-funobactam versus imipenem-cilastatin-relebactam in patients with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia: a phase 3, double-blind, non-inferiority randomised trial

Imipenem-cilastatin-funobactam is statistically non-inferior to imipenem-cilastatin-relebactam for 14-day all-cause risk of death in patients with HABP and VABP with a favourable safety profile. New antibiotics are urgently needed for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readThe Lancet Infectious DiseasesNov 4, 2026

CARDIOLOGY · RANDOMIZED CLINICAL TRIAL

Intensive vs More Intensive Lipid-Lowering Therapy and Plaque Regression in Statin-Naive Patients: Prespecified Analyses From the FLOWPROMOTE Randomized Clinical Trial

This secondary analysis of the FLOWPROMOTE randomized clinical trial demonstrated that in statin-naive patients with CAD, more intensive lipid-lowering therapy was associated with significantly greater regression of total and noncalcified coronary plaque burden compared with intensive therapy. The extent of plaque regression was related to achieved LDL-C levels, supporting the potential for partial reversal of coronary atherosclerosis with intensive lipid reduction.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readJAMA CardiologyOct 30, 2026

GASTROENTEROLOGY · PRECLINICAL

Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-Resistant Pancreatic Cancer

Acquired gemcitabine resistance drives metabolic reprogramming that suppresses pyrimidine salvage while creating a therapeutically exploitable dependence on the mevalonate pathway. These findings identify pharmacologic inhibition of HMGCR as a metabolic vulnerability in gemcitabine resistance and support HMGCR expression as a candidate biomarker (measurable biological signal) for treatment stratification in PDAC patients.

2/5 Preclinical

Evidence Meter · 2/5

Animal & Preclinical Data

Demonstrated in living animal models before large-scale human safety and dosing trials begin.

1 min readGastroenterologyOct 21, 2026

CARDIOLOGY · REAL-WORLD COHORT

Familial hypercholesterolaemia and thymic ageing in a Chinese cohort

Hypercholesterolaemia was associated with reduced thymic output, while statin-treated patients showed partially preserved circulating CD4+ RTE levels, supporting integrated metabolic and immunologic strategies for FH management. Lifelong exposure to elevated low-density lipoprotein cholesterol in familial hypercholesterolaemia (FH) patients not only increases the risk of atherosclerotic cardiovascular disease, but also affects other organs beyond the cardiovascular system.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readEuropean Heart JournalOct 20, 2026

Showing 12 of 14 medical briefings

Interactive Fact Check